Friday, 20 Oct 2017

TNF inhibitor

Datesort ascending Type Title Save
05 Dec 2016 News Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study
01 Dec 2016 Social Good overview TB risk on TNFi (0.79%), all tx & recovered but 1 death. 76% restarted TNFi with only 1.3% TB recurr https://t.co/DQbeFmWmLX
21 Nov 2016 Social Retrosp study of Humira in 40 pts (66 eyes) w/ Behcets ocular dz showed signif less flares (200-->8.5/100PY) w/ ADA https://t.co/t8ldrYptGD
17 Nov 2016 Social RT @emartinmola: No chance for TNF blockers to improve Sjogren's syndrome https://t.co/B8HQF6QGzq
31 Oct 2016 Slide of the day 3 New TNF Inhibitor Biosimilars Approved in 2016
26 Oct 2016 Social Panel of neutrophil genes may be highly predictive of TNFi response in RA pts; CMPK2, IFIT1B, and RNASE3 https://t.co/4jjaHdgGgQ
26 Oct 2016 Social In Ireland, Pfizer has cut the price of Enbrel to match the price of Benepali - an ETN biosimilar. https://t.co/AKdp5bhHoc
24 Oct 2016 Social J&J will compete w/ price of Inflectra through a variety of innovative contracting options, discounts & rebates to payers, providers, & PBMs
19 Oct 2016 News Nor-Switch Study Shows it's Safe to Switch to a Biosimilar
18 Oct 2016 Social TNF inhibitor use in 16 renal transplant pts w/ good efficacy, no decline in GFR x2yrs, but 1/2 had Serious infxns https://t.co/2UHyaiVOpM
18 Oct 2016 News Inflectra Biosimilar Ships in Late November 2016
06 Oct 2016 Social IRAK3 rs11541076 polymorphism yields 33% increase odds of response to TNFi. NLRP3 rs461266 has 25% fewer responses. https://t.co/qIuf7dJKU3
05 Oct 2016 News Infection Rates Stable in JIA With Anti-TNF Therapy
03 Oct 2016 Social Mayo study of incident Sarcoidosis shows 3 fold higher risk of Venous thrombosis & 4 fold risk of pulm embolism. https://t.co/3Gv1bAumBf
26 Sep 2016 News FDA Approves New Amgen Biosimilar for Adalimumab
18 Sep 2016 Social TNFi induced Psoriasis can be treated w/ TNFi D/C, another TNFi (48-85% recurrence) or Stelara. Good short review https://t.co/t2Hb7kA4ru
16 Sep 2016 Social Humira price has increased 6% q 3month for 3 yrs - now $15 billion/yr in USA - what wil happen when biosimilars hi https://t.co/gmX8TeD4ll
31 Aug 2016 News Another Biosimilar Approval - Etanercep-szzs by Novartis
30 Aug 2016 Social Drug retention rates are same between elderly and younger RA pts on TNFi. D/C for AE in old and efficacy in young. https://t.co/ZPXlXvVpTS
29 Aug 2016 Slide of the day Non-Tuberculous Mycobacterial Infection are Common with TNF Inhibitors